Genetron Health to Participate in the Credit Suisse Asian Investment Conference
Genetron Holdings Limited (Nasdaq: GTH), a leader in precision oncology in China, announced participation in the 25th Credit Suisse Asian Investment Conference. Management members, CEO Sizhen Wang and CFO Evan Yu, will hold virtual investor meetings on March 30, 2022.
Genetron specializes in molecular profiling tests, early cancer screening, and companion diagnostics, utilizing advanced technologies in molecular biology and data science for cancer treatment. For more details, interested parties can reach out to Credit Suisse for more information.
- None.
- None.
BEIJING, March 21, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will attend virtual investor meetings at the 25th Credit Suisse Asian Investment Conference.
Genetron’s Management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan Yu, Chief Financial Officer, will attend investor meetings on Wednesday, March 30th, 2022.
Interested parties may request more information by contacting their sales representative at Credit Suisse.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq:GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255
Philip Taylor
Principal | Gilmartin Group
Email: philip@gilmartinir.com
Phone: (415) 937-5406
FAQ
What is Genetron Holdings Limited's focus in the oncology field?
When will Genetron Holdings participate in the Credit Suisse Asian Investment Conference?
Who will represent Genetron Holdings at the investor meetings?
How can interested parties learn more about Genetron Holdings?
What is the stock symbol for Genetron Holdings?
